53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
Hyfe pilot study tests a digital therapeutic combining passive cough monitoring with behavioral suppression techniques delivered through the CoughPro app.
This narrative review by Hyfe's R&D team makes the case that continuous cough monitoring (CCM), powered by acoustic AI, transforms cough from a subjective symptom into a quantifiable digital biomarker.
Independent ERS 2025 NeuroCOUGH trial uses the Hyfe Cough Tracker to test feasibility of studying azithromycin's effect on cough and oesophageal motility.
Independent ERS 2025 trial uses the Hyfe Cough Tracker to show azithromycin reduces objective cough frequency by week one in chronic respiratory disease.
01.03.2023
This paper focuses on the potential of using cough frequency as a biomarker for tuberculosis (TB) diagnosis and monitoring treatment response. The study underscores the significance of continuous cough monitoring as a non-invasive method, which could aid in reducing overtreatment in individuals without TB and improve detection in cases missed by standard symptom-based screenings. This approach represents a significant advance in TB management, offering a more precise and patient-friendly diagnostic tool.
The study also highlights the possibility of reducing overtreatment in individuals who do not have TB and emphasizes the importance of innovative digital biomarkers in enhancing TB management, offering a more precise and patient-friendly diagnostic tool.
